Current opinion in rheumatology最新文献_第2页

The current clinical trial landscape in idiopathic inflammatory myopathies. 特发性炎性肌病的临床试验现状。

IF 5.4 2区医学

Current opinion in rheumatology Pub Date : 2026-11-01 Epub Date: 2026-08-26 DOI: 10.1097/BOR.0000000000001189

Nikola Wilk, Julie Paik, Merrilee Needham, Hector Chinoy

{"title":"The current clinical trial landscape in idiopathic inflammatory myopathies.","authors":"Nikola Wilk, Julie Paik, Merrilee Needham, Hector Chinoy","doi":"10.1097/BOR.0000000000001189","DOIUrl":"10.1097/BOR.0000000000001189","url":null,"abstract":"Purpose of review: In recent years, advances in the understanding of idiopathic inflammatory myopathies (IIM) pathogenesis have led to the development of targeted therapies directed against key immune pathways. This review highlights recent advances in clinical trials, emerging therapeutic strategies, and the rapidly evolving treatment landscape in IIM, reflecting the continued expansion of the therapeutic armamentarium.Recent findings: Multiple clinical trials have evaluated therapeutics directed against key immune pathways implicated in IIM, including B-cell depletion, T-cell co-stimulation, type I interferon (IFN) signaling, fragment crystallizable receptor (FcRn) inhibition and Janus kinase (JAK) /STAT blockade. Promising results have been reported with agents such as JAK inhibitors, FcRn antagonists, anti-IFN therapies, and chimeric antigen receptor (CAR) T-cell approaches in selected patients. Several additional experimental trials are ongoing to evaluate novel therapeutic agents.Summary: Several recent landmarks clinical trials in IIM suggest that targeted therapies directed at key immune pathways may improve disease control beyond conventional immunosuppression, supporting a shift toward mechanism-based treatment approaches in clinical practice. The rapid and expanding growth of clinical studies in IIM reflects an unprecedented acceleration in therapeutic development, underscoring the progress in the field.","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":" ","pages":"488-498"},"PeriodicalIF":5.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148817861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Environmental exposures and risks for the idiopathic inflammatory myopathies and its phenotypes: a narrative review. 环境暴露和特发性炎性肌病及其表型的风险：叙述性回顾。

IF 5.4 2区医学

Current opinion in rheumatology Pub Date : 2026-11-01 Epub Date: 2026-09-01 DOI: 10.1097/BOR.0000000000001184

Taanya Talreja, Latika Gupta, Rishi Balse, Frederick W Miller, Lisa G Rider, Adam Schiffenbauer

{"title":"Environmental exposures and risks for the idiopathic inflammatory myopathies and its phenotypes: a narrative review.","authors":"Taanya Talreja, Latika Gupta, Rishi Balse, Frederick W Miller, Lisa G Rider, Adam Schiffenbauer","doi":"10.1097/BOR.0000000000001184","DOIUrl":"10.1097/BOR.0000000000001184","url":null,"abstract":"Purpose of review: The delineation of myositis-specific autoantibody (MSA) subgroups over the past two decades has reframed environmental research in idiopathic inflammatory myopathies (IIMs), making it plausible to examine discrete exposure-phenotype pairings within serologically defined subgroups. This review synthesises evidence on environmental, occupational, infectious, and pharmacological exposures, with attention to phenotypic specificity.Recent findings: Ultraviolet radiation shapes MSA-specific geographic distributions at the population level and associates with dermatomyositis onset at the individual level. Disease onset follows MSA-specific seasonal patterns, replicated across geographically independent cohorts. Smoking amplifies antisynthetase syndrome risk through a gene-environment interaction with HLA-DRB1*03:01, whilst protecting against anti-TIF1-γ autoantibodies. Gestational and early-life tobacco smoke exposure is consistently implicated as risks for juvenile IIM. Occupational silica exposure associates with antisynthetase syndrome and overlap myositis, with synergistic lung disease risk when combined with smoking. Statins, immune checkpoint inhibitors, anti-TNFα agents, and interferons each induce immunopathologically distinct myositis phenotypes. Postpandemic surveillance has documented a rise in anti-MDA5 autoantibody-positive disease following SARS-CoV-2 infection.Summary: Environmental exposures in IIM act preferentially in specific serological and genetic contexts, consistent with discrete exposure-phenotype pairings shaped by genetic background and age at exposure. Prospective, MSA-stratified studies with direct exposure quantification represent priority directions for the field.","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":" ","pages":"437-447"},"PeriodicalIF":5.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hyper-aging in systemic sclerosis: linking genome instability, mitochondrial dysfunction, and inflammaging to fibrosis. 系统性硬化症中的超衰老：将基因组不稳定、线粒体功能障碍和炎症与纤维化联系起来。

IF 5.4 2区医学

Current opinion in rheumatology Pub Date : 2026-11-01 Epub Date: 2026-08-05 DOI: 10.1097/BOR.0000000000001181

Mohammad Waseem, Azait Imtiaz, Amit Datta, Rafael Contreras-Galindo

{"title":"Hyper-aging in systemic sclerosis: linking genome instability, mitochondrial dysfunction, and inflammaging to fibrosis.","authors":"Mohammad Waseem, Azait Imtiaz, Amit Datta, Rafael Contreras-Galindo","doi":"10.1097/BOR.0000000000001181","DOIUrl":"10.1097/BOR.0000000000001181","url":null,"abstract":"Purpose of review: Systemic sclerosis (SSc) is a progressive autoimmune disease characterized by fibrosis, vasculopathy, and immune dysregulation. Emerging evidence indicates that SSc shares multiple hallmarks of accelerated biological aging, including genomic instability, telomere attrition, mitochondrial dysfunction, cellular senescence, and chronic innate immune activation. This review summarizes recent advances published during the last 18 months supporting the concept of SSc as a disorder of maladaptive or 'hyper-aging'.Recent findings: Recent epigenetic clock studies, including DunedinPACE and other DNA methylation-based aging models, demonstrate accelerated biological aging in SSc, particularly in patients with interstitial lung disease and severe organ involvement. Gene expression meta-analysis has confirmed that aging and senescence signatures are markedly enriched in SSc-ILD lung tissue. Multiple aging-associated mechanisms contribute to disease progression, including telomere shortening, mitochondrial dysfunction, micronuclei formation, and chromosomal instability. Cytosolic DNA derived from damaged nuclei or mitochondria activates the cGAS-STING pathway, sustaining type I interferon signaling, inflammaging, and fibrotic remodeling. Recent transcriptomic and spatial studies further support a close relationship between metabolic collapse, mitochondrial stress, immune dysregulation, and tissue fibrosis in SSc.Summary: Current evidence supports the concept that SSc represents a state of accelerated and dysregulated biological aging involving persistent innate immune activation, mitochondrial stress, and defective genome surveillance. Therapeutic strategies targeting aging-associated pathways, particularly mitochondrial dysfunction, cGAS-STING signaling, and cellular senescence, may provide new opportunities to modulate fibrosis, inflammation, and immune imbalance in SSc.","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":" ","pages":"378-386"},"PeriodicalIF":5.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148677445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond weakness: pain and other under-studied symptoms in adults with inflammatory myopathies. 除了虚弱：炎症性肌病患者的疼痛和其他未充分研究的症状。

IF 5.4 2区医学

Current opinion in rheumatology Pub Date : 2026-11-01 Epub Date: 2026-08-26 DOI: 10.1097/BOR.0000000000001188

Karin Lodin, Helene Alexanderson, Didem Saygin

{"title":"Beyond weakness: pain and other under-studied symptoms in adults with inflammatory myopathies.","authors":"Karin Lodin, Helene Alexanderson, Didem Saygin","doi":"10.1097/BOR.0000000000001188","DOIUrl":"10.1097/BOR.0000000000001188","url":null,"abstract":"Purpose of review: Idiopathic inflammatory myopathies (IIM) are heterogeneous autoimmune diseases with a broad and often underappreciated symptom burden extending beyond organ-specific manifestations. While traditional research has emphasized muscle weakness and other clinical features, less visible symptoms remain insufficiently captured. This review highlights these under-recognized but impactful domains for patients living with IIM.Recent findings: Pain, fatigue, depression, incontinence, sleep disturbance, cognitive dysfunction, and sexual dysfunction are common, inter-related, and closely linked to disease activity and functional impairment, and significantly impact health-related quality of life among patients with IIM. While recent studies increasingly demonstrate pain and fatigue as the key drivers of patient-perceived disease burden, the research studies on other domains are scarce.Summary: This review highlights the importance and prevalence of several under-recognized patient-prioritized symptoms and identifies the areas of critical knowledge gaps that warrant further investigation. Holistic and patient-centered management approach in IIM involves adoption of patient reported outcome measures assessing these key disease aspects and multidisciplinary teams that are equipped with diverse skillsets to improve patient outcomes.","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":" ","pages":"431-436"},"PeriodicalIF":5.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148817815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 5.4 2区医学

Current opinion in rheumatology Pub Date : 2026-11-01 Epub Date: 2026-09-09 DOI: 10.1097/BOR.0000000000001192

Will T Mitchell, Austin M Wheeler

{"title":"Colchicine-related effects on gene and protein expression in gout.","authors":"Will T Mitchell, Austin M Wheeler","doi":"10.1097/BOR.0000000000001192","DOIUrl":"10.1097/BOR.0000000000001192","url":null,"abstract":"Purpose of review: Gout is an inflammatory arthritis mediated by monosodium urate deposition in synovial tissue. Colchicine is a common treatment for acute gout flares and prophylaxis, with well established efficacy but an incompletely understood mechanism. Investigating colchicine's impact at a proteomic and transcriptomic level may highlight these mechanisms. Interest in colchicine's effect on atherosclerotic cardiovascular disease (ASCVD) has stimulated additional research in this area.Recent findings: Proteomic studies have helped identify gout's inflammatory signature, supporting prior evidence of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome activation and involvement of inflammatory signaling pathways. Comparing recent 'omics studies between gout and colchicine use in ASCVD models reveals an overlap in inflammatory pathways. Colchicine reduced innate immune system activation in four separate ASCVD models, with notable overlap in mediators of the NLRP3 inflammasome [interleukin (IL)-1β, IL-6, IL-18, and monocyte chemotactic protein-1] and others.Summary: Building on recent studies of colchicine's effect in ASCVD and the overlap seen with pathways implicated in gout, proteomic and transcriptomic studies in gout could further our understanding of the mechanisms driving colchicine's effectiveness. A more complete understanding of colchicine's mechanisms of action in gout may help guide future efforts at development of more targeted approaches to gout treatment.","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":" ","pages":"401-411"},"PeriodicalIF":5.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148911202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathogenesis of autoantibodies in inflammatory myopathies. 炎性肌病中自身抗体的发病机制。

IF 5.4 2区医学

Current opinion in rheumatology Pub Date : 2026-11-01 Epub Date: 2026-09-01 DOI: 10.1097/BOR.0000000000001196

Katharine Ching Chung, Qianzi Zhao, Iago Pinal-Fernandez

{"title":"Pathogenesis of autoantibodies in inflammatory myopathies.","authors":"Katharine Ching Chung, Qianzi Zhao, Iago Pinal-Fernandez","doi":"10.1097/BOR.0000000000001196","DOIUrl":"10.1097/BOR.0000000000001196","url":null,"abstract":"Purpose of review: While autoantibodies targeting extracellular antigens, such as those in myasthenia gravis, are established mediators of disease, autoantibodies recognizing intracellular antigens in inflammatory myopathies have traditionally been considered nonpathogenic. This review examines evidence challenging that paradigm and highlights recent advances in understanding the origins and pathogenic functions of autoantibodies in myositis.Recent findings: In several forms of myositis, immunoglobulin accumulates within muscle fibers in a distribution mirroring that of the cognate autoantigen. Muscle biopsies demonstrate functional consequences consistent with disruption of the targeted autoantigen, as well as secondary muscle damage and inflammation. These effects are reproduced in vitro by forced autoantibody internalization. Local plasma cells may facilitate this process by releasing cytoplasmic contents into neighboring cells, including immunoglobulin RNA. In paraneoplastic dermatomyositis, genetic alterations of the targeted autoantigen are frequently identified in tumors, suggesting that immune responses to somatic tumor mutations may initiate autoantibody production. In immune checkpoint inhibitor-associated myositis, autoantibodies may contribute to disease by acting as chemoattractants for drug-activated T cells.Summary: Recent findings support a direct pathogenic role for autoantibodies in several autoantibody-defined myositis subtypes and provide new insights into their origins and contribution to immune-mediated muscle injury, while also suggesting broader roles.","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":" ","pages":"448-455"},"PeriodicalIF":5.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148873085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Partners in discovery: building equal and proactive patient engagement in inflammatory myopathies. 发现合作伙伴：在炎性肌病中建立平等和主动的患者参与。

IF 5.4 2区医学

Current opinion in rheumatology Pub Date : 2026-11-01 Epub Date: 2026-09-01 DOI: 10.1097/BOR.0000000000001197

Karen Cheng, Valérie Leclair

{"title":"Partners in discovery: building equal and proactive patient engagement in inflammatory myopathies.","authors":"Karen Cheng, Valérie Leclair","doi":"10.1097/BOR.0000000000001197","DOIUrl":"10.1097/BOR.0000000000001197","url":null,"abstract":"Purpose of review: Patient engagement in research has evolved from passive participation and inclusion toward active partnership and co-leadership. This review examines the current landscape of patient involvement in myositis research, highlights existing initiatives and frameworks, and identifies persistent gaps and overlaps.Recent findings: In myositis, or inflammatory myopathies, early onboarding and integration of patients as research partners in preclinical and clinical studies offer invaluable opportunities to improve relevance, feasibility, and impact of research. The findings presented emphasize the importance of early partnership with patient research partners (PRPs), bidirectional training to foster mutual understanding, and expanded outreach to underrepresented regions.Summary: Patient engagement in myositis research has advanced considerably, yet its integration remains inconsistent worldwide. Several existing resources can be leveraged to facilitate patient engagement in myositis research, but achieving meaningful PRP integration requires deliberate effort, adequate resources, and a commitment to cultural change.","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":" ","pages":"423-430"},"PeriodicalIF":5.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systemic sclerosis in 2026: emerging paradigms from the World Scleroderma Congress. 2026年的系统性硬化症：来自世界硬皮病大会的新范例。

IF 5.4 2区医学

Current opinion in rheumatology Pub Date : 2026-10-20 DOI: 10.1097/BOR.0000000000001204

Cristiana Sieiro Santos, Yannick Allanore, Marco Matucci-Cerinic

{"title":"Systemic sclerosis in 2026: emerging paradigms from the World Scleroderma Congress.","authors":"Cristiana Sieiro Santos, Yannick Allanore, Marco Matucci-Cerinic","doi":"10.1097/BOR.0000000000001204","DOIUrl":"https://doi.org/10.1097/BOR.0000000000001204","url":null,"abstract":"Purpose of review: To summarize recent advances in systemic sclerosis (SSc) highlighted at the 2026 World Scleroderma Congress, focusing on early disease, immunovascular mechanisms, and emerging therapeutic strategies.Recent findings: Recent data support a paradigm shift in SSc, demonstrating that disease onset occurs during a very early phase (VEDOSS) characterized by early immune activation and microvascular dysfunction. Type I interferon-driven pathways are increasingly implicated in vascular and myocardial involvement, reinforcing the concept of a shared immunovascular axis across organ systems. Advances in multimodal imaging and circulating biomarkers enable detection of subclinical organ disease, while multi-omic and data-driven approaches are redefining disease subsets beyond traditional classifications. In parallel, novel therapeutic strategies - including targeted immune modulation, autologous haematopoietic stem cell transplantation (AHSCT), and emerging CAR-T approaches - are driving a transition toward earlier, mechanism-based intervention.Summary: Systemic sclerosis is increasingly understood as a dynamic continuum of autoimmune/inflammatory and fibrotic mechanisms that can be identified through imaging, biohumoral, and functional insights, thus enabling a very early/early diagnosis, a risk stratification, and a precision-based therapeutic approach.","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rheumatological manifestations of Lyme disease and related tick-borne diseases in north America. 北美莱姆病和相关蜱传疾病的风湿病表现。

IF 5.4 2区医学

Current opinion in rheumatology Pub Date : 2026-10-20 DOI: 10.1097/BOR.0000000000001193

Blerta Green, Yasmin Jaber, Robert T Schoen

{"title":"Rheumatological manifestations of Lyme disease and related tick-borne diseases in north America.","authors":"Blerta Green, Yasmin Jaber, Robert T Schoen","doi":"10.1097/BOR.0000000000001193","DOIUrl":"10.1097/BOR.0000000000001193","url":null,"abstract":"Purpose of review: Lyme disease is the most common vector-borne infection in North America, and the incidence continues to rise as the geographic range of Ixodes ticks expands. While most patients can be cured with early antibiotic therapy, Lyme arthritis persists as a challenging late manifestation, with a subset developing postantibiotic inflammatory disease that mimics autoimmune arthritis.Recent findings: Recent studies have advanced our understanding of Lyme arthritis. Even after bacterial eradication, in some patients, residual antigens in the synovial fluid can sustain immune activation. Immunologic studies demonstrate specific HLA-DRB1 alleles associated with postantibiotic Lyme arthritis, suggesting a predisposition to chronic inflammation. These findings demonstrate that Lyme arthritis is a complex immune-mediated disorder that bridges infectious and autoimmune mechanisms.Summary: Antibiotic therapy is effective for most patients with Lyme arthritis, but optimal management for patients with postantibiotic Lyme arthritis is still uncertain. Continued research into the pathogenesis of postantibiotic Lyme arthritis will be key to improving diagnostic accuracy, refining treatment algorithms, and preventing chronic morbidity associated with Lyme arthritis.","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148817811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The eye in systemic vasculitis. 全身性血管炎的眼睛。

IF 5.4 2区医学

Current opinion in rheumatology Pub Date : 2026-10-20 DOI: 10.1097/BOR.0000000000001191

Hilal Eser-Ozturk, Ilknur Tugal-Tutkun

{"title":"The eye in systemic vasculitis.","authors":"Hilal Eser-Ozturk, Ilknur Tugal-Tutkun","doi":"10.1097/BOR.0000000000001191","DOIUrl":"10.1097/BOR.0000000000001191","url":null,"abstract":"Purpose of review: This review summarizes the spectrum of ocular manifestations in systemic vasculitis, emphasizing recent advances in clinical recognition, multimodal imaging, biomarkers, and targeted treatment.Recent findings: Ocular involvement may precede systemic manifestations and affect the anterior segment, retina, choroid, optic nerve, or orbit. In giant cell arteritis, vascular ultrasound is a preferred first-line imaging modality, while orbital and retinal imaging may provide complementary information on ischemic injury and treatment response. Ultra-widefield fluorescein angiography improves the detection of peripheral retinal nonperfusion in Takayasu arteritis. In antineutrophil cytoplasmic antibody-associated vasculitis, particularly granulomatosis with polyangiitis, ocular or orbital inflammation may be the initial or isolated manifestation, and rituximab-based therapy has been associated with favorable outcomes in orbital inflammatory disease. In Behçet uveitis, ocular-specific diagnostic criteria, imaging biomarkers, and treat-to-target biologic strategies are emerging. However, many of these approaches require validation in larger prospective studies.Summary: Prompt recognition and multidisciplinary management are essential to prevent irreversible visual loss. New imaging methods and targeted therapies have broadened diagnostic and therapeutic options. Despite these advances, standardized ocular outcome measures and validation of emerging imaging and molecular biomarkers remain important priorities.","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148817235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0